Ten Years On, Diabetes Remission Persists for About Half of Gastric-Bypass Patients

Roughly half of the patients who had a gastric bypass were still free of type 2 diabetes ten years later, while remission held for about a quarter of those who had a sleeve gastrectomy or a lesser-used stomach-folding operation. That is the headline from a long-term extension of a small Spanish randomized trial, published in Clinical Nutrition and registered on the ISRCTN registry.

The result is neither a cure story nor a cautionary tale. It is a measurement of durability — and a reminder that surgical diabetes remission is real, reproducible, and rarely permanent.

What the trial actually did

The trial, called DIABETCIR, was run at Bellvitge University Hospital in Barcelona. It enrolled adults with severe obesity and type 2 diabetes and assigned them, one-to-one-to-one, to three operations: a metabolic gastric bypass with a long biliopancreatic limb, a sleeve gastrectomy, or greater curvature plication — a restrictive technique that folds the stomach without removing tissue or rerouting the intestine. A single surgeon performed every procedure laparoscopically, which controls for technique but also means the findings reflect one operator and one institution.

Forty-five people were randomized. By the ten-year mark, 93% were still providing data, an unusually high retention rate for a study of this length. The design is a genuine randomized controlled trial, the strongest form of clinical evidence — but its size, its single centre and the fact that neither patients nor investigators were blinded mean the results should be read as a precise signal, not a definitive verdict.

Bypass leads early; the gap narrows later

At both one year and five years the bypass group showed the greatest weight loss and the best metabolic control. A decade in, that advantage had visibly attenuated. The remission counts, though, still tilted toward bypass:

The plication arm is the unusual one. The operation is rarely used in routine practice, so a decade of follow-up on it is scarce; its remission rate landed close to the sleeve’s, which is the more clinically familiar comparison. The investigators also reported that a higher probability of remission over time was seen after bypass compared with the other two techniques.

Relapse is common — and that is not the whole story

Between roughly 42% and 50% of participants who reached remission eventually relapsed, depending on the operation. Reported that way, the glass looks half empty.

A second measure looks different. Use of glucose-lowering medication fell substantially in every group, and most sharply after gastric bypass. A patient who no longer meets a strict biochemical definition of remission but who has halved their medication burden has still gained something durable and clinically meaningful. Narrow, binary definitions of remission are useful for research; they can understate what surgery does over ten years.

The clues show up in year one

Three factors tracked with long-term remission regardless of which operation a patient received: a shorter history of type 2 diabetes before surgery, a larger early rise in GLP-1 — a gut hormone measured after a standard test meal — and more weight lost within the first postoperative year. The trial was designed in part to test whether the incretin response explains why surgery improves glucose control beyond weight loss alone, and the ten-year data keep that mechanism in play.

None of these are levers a patient can pull directly. They are, instead, the kind of prognostic information that might eventually inform how clinicians frame expectations and follow-up.

Where this fits the wider evidence

Durability has been the open question since the first randomized comparisons. A five-year follow-up of an open-label single-centre randomized trial, published in The Lancet in 2015, found remission sustained in a substantial minority of surgical patients — and in none of those managed with conventional medical therapy alone. That study, too, was small and single-centre, and the new paper extends the same line of inquiry a further five years.

Observational research supplies the other half of the picture. The LABS study, funded by NIDDK and conducted as a multi-centre prospective cohort, followed thousands of patients after bariatric surgery; at its seven-year follow-up, participants averaged a 28.4% loss of body weight after gastric bypass and 14.9% after gastric banding, with annual data collection through 2015. LABS measured outcomes and safety at a scale no randomized trial has matched, while trials such as DIABETCIR measure specific mechanisms under controlled conditions. The two kinds of evidence are complementary, not competing.

What the new extension cannot settle is generalizability: 45 patients, one centre, one surgeon, one country. Larger randomized studies with standardized remission definitions and multi-decade follow-up remain the missing piece. For now, the decade-long numbers add a sober, useful data point to a debate that has always been about time.

This article reports published research and clinical-trial results. It is not medical advice. NIDDK Labs Archive is an independent informational resource and is not affiliated with the NIH, NIDDK, or the LABS research group; references to LABS describe that NIDDK-funded study, not this site’s own work.